Iktos
AI and robotics platform for autonomous small molecule drug discovery
Iktos is the most comprehensive AI+robotics platform for large pharma ready to automate DMTA. It excels at challenging targets and integrates generative design with retrosynthesis and lab automation. However, the hardware commitment and undisclosed pricing make it impractical for smaller teams.
- Large pharma companies investing in full DMTA automation
- Teams targeting protein-protein interactions, molecular glues, or PROTACs
- Organizations wanting to compress discovery timelines to under 2 years
- Medicinal and computational chemistry teams needing AI with synthetic accessibility focus
- Academic labs or small biotechs with limited budget for enterprise robotics
- Teams needing only a retrosynthesis tool without automation (use Spaya standalone)
- Researchers focused on biologics, antibodies, or gene therapies
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Iktos if you cannot invest $1M+ in robotic lab infrastructure or if you need a purely in silico tool without hardware integration.
Robotic hardware (Chemspeed or equivalent) not included in software pricing
Iktos pricing is undisclosed but targets enterprise pharma budgets, likely $100K+/year for software plus hardware costs. Cheaper alternatives like ChemCrow (open-source) or ASKCOS (free) exist for design/retrosynthesis alone, but lack automation. For full DMTA, Recursion's platform may offer comparable value at scale.
In short
Iktos — AI and robotics platform for autonomous small molecule drug discovery. Best for Large pharma companies investing in full DMTA automation, Teams targeting protein-protein interactions, molecular glues, or PROTACs, Organizations wanting to compress discovery timelines to under 2 years. Contact Sales pricing.
What's new in Iktos
Checked 11 days agoAcross the latest 3 updates: 1 launch and 2 changelog entries.
Iktos Engine: APIs for Agentic workflows and Computational Chemistry Pipelines
Iktos Engine launches APIs enabling agentic workflows and integration of computational chemistry pipelines into drug discovery processes.
Iktos announces a new partnership with Chemspeed to help pharmaceutical companies unlock new possibilities in automated chemical research
Iktos partners with Chemspeed to enhance robotic integration for automated chemical research, expanding DMTA capabilities.
Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration
Pierre Fabre Laboratories partners with Iktos for integrated drug discovery, leveraging Iktos's AI and robotics platform.
Viability Score
How likely is Iktos to still be operational in 12 months? Based on 4 signals — momentum (how recently it shipped), wrapper dependency, revenue model, and web presence.
Last calculated: July 2026
How we score →Key Features
- Generative AI for de novo drug design (Makya 2.0)
- Multi-parametric optimization with ML models
- 3D constraint inclusion in molecular design
- Synthetic accessibility guarantee in generated molecules
- Real-time retrosynthetic route display (Spaya)
- Customizable synthesis steps and constraints
- Integration with multiple data providers for retrosynthesis
- Fully automated synthesis, purification, analysis (Iktos Robotics)
- High-throughput DMTA cycle automation
- Workflow management and raw material ordering
- Multidimensional biological data from imaging platform
- In-cellulo screening for relevant biological context
- Identification of modulators for protein-protein and RNA-protein interactions
- Molecular glues and PROTACs design support
- Agentic workflow APIs (Iktos Engine, 2026)
About Iktos
Iktos combines generative AI with robotics to accelerate small molecule drug discovery, offering an end-to-end platform that integrates AI-driven design, retrosynthesis planning, and automated lab execution. Its flagship product, Makya 2.0, is a generative AI SaaS platform for de novo drug design with enhanced data analysis and visualization, ensuring synthetically accessible molecules. Spaya provides AI-driven retrosynthesis with real-time route display and customizable constraints. Iktos Robotics automates the entire DMTA cycle—from workflow management to synthesis, purification, and biological testing—reducing discovery timelines to under 2 years. The platform supports multi-parametric optimization, 3D constraints, and challenging targets like protein-protein interactions, molecular glues, and PROTACs. With over 60 collaborations and recent partnerships with Chemspeed for expanded robotic integration, Iktos competes as an integrated solution, though it requires significant investment in robotics infrastructure, making it best suited for large pharmaceutical companies seeking fully autonomous labs. The newly announced Iktos Engine (2026) provides APIs for agentic workflows and computational chemistry pipelines, marking a shift toward modular integration.
Behind the Verdict
Iktos delivers on the promise of autonomous drug discovery, but it's not for everyone. If you're a large pharma company with the budget to invest in robotics infrastructure, it's arguably the most complete solution on the market—covering design, synthesis, and testing in one loop. The platform's ability to handle protein-protein interactions, molecular glues, and PROTACs is a genuine differentiator; few AI tools address those targets effectively. The news of Iktos Engine (APIs for agentic workflows) signals a move toward modularity, which could make parts of the platform accessible to teams that don't want the full robotics suite. On the flip side, the pricing is opaque and likely enterprise-level. Academic labs and small biotechs should look elsewhere—perhaps at standalone generative AI tools like Makya if offered separately, or pure retrosynthesis with Spaya. Compared to competitors like Recursion or Insilico, Iktos's advantage is the tight integration of AI with physical automation, but that also locks you into their ecosystem. In practice, the DMTA cycle speed claim (<2 years) is impressive, but we'd want to see third-party validation before betting a pipeline on it. For now, Iktos is best for organizations ready to make a long-term, capital-intensive commitment to autonomous labs.
Researching Iktos? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Iktos actually fits — and what changes day-one when you adopt it.
You need to generate novel, synthetically accessible lead series for a challenging kinase target (e.g., PolQ).
Outcome: Within days, Makya 2.0 proposes 100+ novel molecules with MPO scores and synthetic routes via Spaya. Top candidates are automatically forwarded to Iktos Robotics for synthesis and testing, delivering validated hits in weeks.
You want to design molecular glues for a protein-protein interaction target without prior structural data.
Outcome: Using Makya's generative AI with 3D constraints and MPO, you generate focused libraries. Spaya provides feasible retrosynthesis paths, and Iktos Robotics synthesizes and screens them in an automated DMTA loop, yielding optimized binders in under 6 months.
Use Cases
- Design novel, synthetically accessible drug candidates using generative AI and validate via automated synthesis
- Plan efficient retrosynthetic routes from target compound to starting materials with Spaya
- Automate the DMTA cycle for hit-to-lead and lead optimization with robotic synthesis and testing
- Identify small-molecule modulators for challenging targets like protein-protein interactions and PROTACs
Models Under the Hood
as of 2026-07-06
Limitations
- Pricing is not publicly disclosed and likely high, requiring a sales contact.
- Full DMTA automation requires integration with robotic hardware (e.g., Chemspeed), which may not be feasible for all labs.
- API access and feature depth may be limited by contract tier.
- The platform's focus is on small-molecule drug discovery; not designed for biologics or clinical-stage development.
as of 2026-06-26
Where the pricing makes sense
The company stage and team size where Iktos's pricing actually pencils out — and where peers do it cheaper.
Iktos pricing is undisclosed but targets enterprise pharma budgets, likely $100K+/year for software plus hardware costs. Cheaper alternatives like ChemCrow (open-source) or ASKCOS (free) exist for design/retrosynthesis alone, but lack automation. For full DMTA, Recursion's platform may offer comparable value at scale.
Setup time & first value
How long it actually takes to get something useful out of Iktos — broken out by persona, not the marketing-page minute.
For a large pharma with existing robotic infrastructure, initial setup (software integration, workflow configuration, and data onboarding) takes 2–4 weeks. Full DMTA loop automation may require 1–3 months for hardware setup (Chemspeed) and custom scripts. Smaller teams without robotics should expect longer integration timelines.
Switching to or from Iktos
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From in-house design tools: Iktos provides data import templates for molecule libraries and assay results (SDF, CSV).
- →From ASKCOS or ChemCrow: Spaya can replace retrosynthesis workflows with its AI-driven routes and commercial availability checks.
- ↗To Recursion: Export molecule data (SDF) and assay results; Recursion's platform may require different format mappings.
- ↗To Schrodinger: Export computational models and molecule sets; Schrodinger's LiveDesign can import SDF and ML models.
Integrations
Resources & Guides
Official links
Tools that pair well with Iktos
Common stack mates teams adopt alongside Iktos, with the specific reason each pairing earns its keep.
Alternatives to Iktos
View all
Nimbus Therapeutics
AI-driven small molecule drug discovery for selective oncology and immunology
Frequently Asked Questions
Categories
Used Iktos? Help shape our editorial sentiment research.